The Relation Between the Initial Value of the Skeletal Mass Index and Pathological Response
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 69
- Locations
- 1
- Primary Endpoint
- Sarcopenic index
Study Overview
Brief Summary
The investigators aimed to accurately measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.
Detailed Description
In patients with operable breast cancer (BC) receiving neoadjuvant chemotherapy (NAC), the pathological response rate was found to be related to body composition. The success of complete pathologic response (pCR) is a known prognostic factor in BC patients treated with NAC. The investigators aimed to accurately measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 29 Years to 72 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Early and locally advanced operated breast cancer patients receiving neoadjuvant chemotherapy.
Exclusion Criteria
- •Patients who did not receive neoadjuvant chemotherapy, had metastatic breast cancer and whose radiological images were not available.
Outcomes
Primary Outcomes
Sarcopenic index
Time Frame: Through study completion, an average of 1 year.
skeletal muscle area (cm2)/height (m2) et L3 level
Secondary Outcomes
- Body mass index(Through study completion, an average of 1 year.)
Investigators
Ebru Yilmaz
Principal Investigator
Acıbadem Atunizade Hospital
